Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Terminated
Trial end date:
2020-06-16
Target enrollment:
Participant gender:
Summary
This partially randomized phase I/II trial studies the side effects and how well sirolimus
works when given together with docetaxel and carboplatin in treating patients with
castration-resistant prostate cancer that has spread to other places in the body
(metastatic). Biological therapies, such as sirolimus, use substances made from living
organisms that may stimulate or suppress the immune system in different ways and stop tumor
cells from growing. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving sirolimus together with
docetaxel and carboplatin may kill more tumor cells.